my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
19-12-2011: NovImmune announced that Genentech, a member of the Roche Group, initiated a First-in-Human study with anti-IL-17 (NI-1401, RG7624), a fully human monoclonal antibody designed to specifically and selectively bind to the human IL-17 family of cytokines. The anti-IL-17 antibody was generated at NovImmune and licensed to Genentech in July 2010. The initiation of the Phase I clinical trial triggers a milestone payment from Genentech of an undisclosed amount.
Jack Barbut, CEO, commented "With the compound entering man, NovImmune is gratified to see Genentech’s continued commitment to the anti-IL-17 program. This news creates an additional milestone as this is the fifth NovImmune therapeutic antibody to enter clinical development; a significant achievement for a small biotech company."
Watchlist
This is where you can add this news to your personal favourites
Genentech Initiates First-in-Human Study with NovImmune’s Anti-IL17 Antibody
NovImmune announced that Genentech, a member of the Roche Group, initiated a First-in-Human study with anti-IL-17 (NI-1401, RG7624), a fully human monoclonal antibody designed to specifically and selectively bind to the human IL-17 family of cytokines. The anti-IL-17 antibody was generated ... more
NovImmune Initiates a Proof-of-Concept Study in Primary Biliary Cirrhosis (PBC)
NovImmune announced that a Proof-of–Concept (PoC) study with NI-0801, a fully human monoclonal antibody neutralizing the CXCL10/Interferon-gamma-inducible protein-10 (IP-10) chemokine, was initiated in patients with PBC. This is a chronic inflammatory, debilitating condition of the bile duc ... more
NovImmune Nominates Klaus Strein as New Member of the Board of Directors
NovImmune announced that Klaus Strein was nominated member of the Board of Directors.Prof Klaus Strein holds a Ph.D. in chemistry from the University of Heidelberg and is also qualified as an M.D. specialized in pharmacology and toxicology. Prof Strein joined Boehringer Mannheim (BM) as Hea ... more
NovImmmune is committed to innovation by discovering and developing therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders. more
Genentech Initiates First-in-Human Study with NovImmune’s Anti-IL17 Antibody
NovImmune announced that Genentech, a member of the Roche Group, initiated a First-in-Human study with anti-IL-17 (NI-1401, RG7624), a fully human monoclonal antibody designed to specifically and selectively bind to the human IL-17 family of cytokines. The anti-IL-17 antibody was generated ... more
Galapagos and Genentech extend drug discovery collaboration
Galapagos NV announced that its service division Argenta has extended its integrated contract drug discovery agreement with Genentech, a member of the Roche Group. Total potential value of the contract extension is up to £21.5 million (€23.4 million). This is the third such extension since ... more
First Patient Dosed in Phase II Clinical Trial for BioInvent's Cardiovascular Drug, BI-204
BioInvent International AB announced the dosing of the first patient in the phase II study of the Company’s antibody, BI-204. The product candidate is being developed for secondary prevention of cardiovascular events in patients with acute coronary syndrome.The Phase II study is a multicen ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
